Bifogade filer
Implementation of incentive program LTIP 2025:1 in Alzinova
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
At the Extraordinary General Meeting of Alzinova AB (publ) ("Alzinova" or the "Company") on 7 March 2025, it was resolved to implement an incentive program ("LTIP 2025:1") consisting of a maximum of 4,000,000 warrants for senior executives, employees and key employees who work on a consulting basis in the Company (the "Participants"). LTIP 2025:1 has now been implemented and Alzinova's board of directors has, in accordance with the guidelines resolved by the AGM, resolved on transfer of 3 250 000 warrants to the Participants.
Julian Aleksov, Chairman of the Board of Alzinova, comments: "Through the recently launched incentive program, we aim to offer our employees the opportunity to take part in the company’s future value creation. Our employees’ expertise and commitment are vital to our continued development, and the program is intended to further strengthen their engagement. We are pleased with the strong interest in participating in the program, which contributes to building a dedicated and long-term team and leadership at Alzinova."
Through the implementation of LTIP 2025:1, a total of 8 Participants have acquired a total of 3 004 000 warrants, which means that 92,4% of issued warrants under LTIP 2025:1 have been transferred to the Participants. The warrants have been transferred according to market terms. Each warrant entitles the holder to subscribe for one new share in the Company during the period from and including 15 March 2027 up to and including 31 March 2027. The subscription price at the time of exercise of the warrants has been set at SEK 5,14 in accordance with the previously communicated terms and conditions.
Number of shares and dilution
As a result of the now communicated implementation of LTIP 2025:1, the total number of shares in the Company, upon full exercise of all now transferred warrants, may increase by a total of 3 004 000 shares and the share capital may increase by a maximum of 790 052 SEK. The total dilution as a result of full exercise of the now transferred warrants under LTIP 2025:1 amounts to approximately 3,26 percent, based on the current number of outstanding votes and shares in the Company.
For more information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com